Magnesium Lactate in the Reduction of Gestational Diabetes Incidence.
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Pregnancy Related
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Study groups: Intervention group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement. Control group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive 2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.Masking: Double (Participant, Care Provider)Masking Description: Neither the patient nor the treating doctor will know the study group the participant was randomized.Primary Purpose: Prevention
Participation Requirements
- Age
- Between 19 years and 35 years
- Gender
- Only males
Description
Objective: This study aims to evaluate the efficacy and safety of magnesium lactate oral administration in reducing the gestational diabetes incidence. Design: Randomized, double-blind, placebo-controlled clinical trial. Study population: Pregnant women aged 19 to 35 years, in the twelfth week of pr...
Objective: This study aims to evaluate the efficacy and safety of magnesium lactate oral administration in reducing the gestational diabetes incidence. Design: Randomized, double-blind, placebo-controlled clinical trial. Study population: Pregnant women aged 19 to 35 years, in the twelfth week of pregnancy, whit hypomagnesemia and without the concomitant disease. Study groups: an intervention group and a control group. Sample size: It was calculated using a statistical power of 80%, an alpha value of 0.05; 15% of the difference in the mean of gestational diabetes incidence control group and intervention groups was considered. The estimated sample size was 110 subjects for each group. Process: All eligible participants according to inclusion and exclusion criteria, will be randomized to one of the study groups. The intervention group will receive magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement; the control group will receive 2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement. The blood concentrations of glucose, triglycerides, magnesium, creatinine, transaminases, and thyroid hormones will be measured, as well as the anthropometric measurements, at baseline and end conditions. Also, an oral glucose tolerance curve will be realized at the 20th gestation week. Statistical analysis: Numerical values will be expressed as mean ± standard deviation; categorical variables will be expressed as proportions. Differences between the groups were estimated by unpaired Student t-test for numerical variables (Mann-Whitney U test for skewed data) or Chi-square and Fisher´s exact test for categorical variables. Intragroup differences were estimated by paired Student t-test.
Tracking Information
- NCT #
- NCT04037098
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Fernando PD Guerrero Instituto Mexicano del Seguro Social Study Chair: Luis PD Simental Instituto Mexicano del Seguro Social Study Chair: Gerardo PD Martínez Instituto Mexicano del Seguro Social Study Chair: Cludia PD Gamboa Instituto Mexicano del Seguro Social